MIRM Stock Forecast & Price Target

Mirum Pharmaceuticals has demonstrated significant growth, with LIVMARLI sales reaching $88.1 million in 2Q25, representing an impressive 87% year-over-year increase from 2Q24. This robust sales performance has prompted the company to raise its 2025 revenue guidance to a range of $490 million to $510 million, indicating a substantial upward revision of $57.5 million at the midpoint. Furthermore, the overall total revenues for 2Q25 amounted to $127.8 million, reflecting a 64% year-over-year growth, which underscores the positive commercial momentum and increasing adoption of LIVMARLI in treating Alagille syndrome and progressive familial intrahepatic cholestasis.

Mirum Pharmaceuticals Inc faces significant challenges due to its lack of composition of matter patent protection for its primary product, maralixibat, leaving it reliant on less robust method of use and formulation patent coverage. The company’s revenue is still in the early growth stage, and there is a potential for unexpected competition and slower sales growth to hinder its path to profitability. Additionally, the presence of multiple alternative ASBT inhibitors in clinical development presents a competitive risk, further complicating Mirum's ability to achieve sustained financial success amid an inherently volatile biotech market.